CRNX short interest jump by 3.67%, reflecting negative sentiment

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Crinetics Pharmaceuticals Inc shares valued at $3,141,877 were sold by Betz Stephen F. on Jun 12 ’25. At $32.23 per share, Betz Stephen F. sold 97,483 shares. The insider’s holdings dropped to 99,713 shares worth approximately $3.04 million following the completion of this transaction.

Also, STEPHEN BETZ purchased 97,483 shares, netting a total of over 3,151,625 in proceeds.

Before that, Pizzuti Dana had sold 2,515 shares from its account. In a trade valued at $86,021, the Chief Med and Dev Officer traded Crinetics Pharmaceuticals Inc shares for $34.20 each. Upon closing the transaction, the insider’s holdings decreased to 2,515 shares, worth approximately $2.2 million.

As published in their initiating research note from Stifel on March 25, 2025, Crinetics Pharmaceuticals Inc [CRNX] has been a Buy and the price target has been revised to $60. Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in mid February. As of February 04, 2025, Wolfe Research has initiated its “Peer perform” rating for CRNX. Earlier on January 22, 2025, Jefferies upgraded its rating. Their new recommendation was “a Buy” for CRNX stock which previously was a “a Hold”.

Analyzing CRNX Stock Performance

On last trading session,, Crinetics Pharmaceuticals Inc [NASDAQ: CRNX] plunged -1.13% to $30.50. The stock’s lowest price that day was $30.44, but it reached a high of $31.56 in the same session. During the last five days, there has been a drop of approximately -5.66%. Over the course of the year, Crinetics Pharmaceuticals Inc shares have dropped approximately -40.35%. Shares of the company reached a 52-week high of $53.55 on 01/03/25 and a 52-week low of $24.10 on 04/09/25.

Support And Resistance Levels for Crinetics Pharmaceuticals Inc (CRNX)

According to the 24-hour chart, there is a support level at 30.09, which, if violated, would cause prices to drop to 29.69. In the upper region, resistance lies at 31.23. The next price resistance is at 31.97. RSI (Relative Strength Index) is 43.00 on the 14-day chart, showing neutral technical sentiment.

Is Crinetics Pharmaceuticals Inc subject to short interest?

Stocks of Crinetics Pharmaceuticals Inc saw a sharp rise in short interest on 2025-05-30 jumping by 0.38 million shares to 10.21 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 9.84 million shares. A jump of 3.67% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 11.14 of the overall float, the days-to-cover ratio (short ratio) jumped to 11.14.

Which companies own the most shares of Crinetics Pharmaceuticals Inc (CRNX)?

In terms of Crinetics Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 75.5 in the next 12 months, up nearly 144.73% from the previous closing price of $30.85. Analysts anticipate Crinetics Pharmaceuticals Inc stock to reach 91 by 2025, with the lowest price target being 60. In spite of this, 5 analysts ranked Crinetics Pharmaceuticals Inc stock as Buy at the end of 2025. On March 06, 2024, Citigroup assigned a price target of “a Buy” to the stock and initiated coverage with a $68.

Most Popular

Knox Daily
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.